BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Data from Israel’s largest health care organization (n=596,618 vaccinated, n=596,618 controls [unvaccinated]), show a high effectiveness of the BNT162b2 vaccine for preventing symptomatic Covid-19 in a non-controlled setting, similar to vaccine efficacy reported in RCT.

Source:

New England Journal of Medicine